Cholera vaccine: new preventive tool for endemic countries - PubMed
Review
doi: 10.4161/hv.19083. Epub 2012 May 1.
Affiliations
- PMID: 22634452
- DOI: 10.4161/hv.19083
Free article
Review
Cholera vaccine: new preventive tool for endemic countries
Ramesh Verma et al. Hum Vaccin Immunother. 2012 May.
Free article
Abstract
Cholera is a major global public health problem and remains an important threat in almost every developing country, especially in areas where population overcrowding and poor sanitation are common, such as slums and refugee camps. Cholera is one of the most dreaded diseases in the world, in some cases leading to death within 24 h if left untreated. Without treatment, severe infection has a mortality rate of 30-50%. In 2007, WHO recorded 177,963 cholera cases and 4,031 deaths worldwide. However, the estimated actual burden of cholera is in the vicinity of 3 to 5 million cases and 100,000 to 130,000 deaths per year. The disease is endemic to parts of Africa, Asia, the Middle East and South America. Large outbreaks are common after natural disasters or in populations displaced by war, where there is inadequate sewage disposal and contaminated water. In India, during the 10-y period (1997-2006) studied, the states having the highest number of reported outbreaks were West Bengal, Orissa, Maharashtra and Kerala, which together accounted for 60% of all reported outbreaks. A review of cholera cases in India reported to WHO from 2003-2007 showed that the numbers were in the few thousands with a case fatality rate of < 1%. However, it is believed that the number of cholera cases and deaths occurring annually in India is much greater than the number reported. A literature review covering a four-year period from 2003 to 2006 found reported cholera outbreaks in 18 of the 35 States and Union Territories of India. Of these, 11 had cholera outbreaks reported for multiple years. Vietnam has produced a cheaper variant of killed whole-cell vaccine devoid of the B subunit. This vaccine contains both Vibrio cholerae O1 and O139, and provides 50 per cent protection for at least three years after vaccination. For endemic cholera, population-level immunity is relatively high, making control possible with relatively low vaccine coverage levels. This vaccine should be used in areas where cholera is endemic, particularly in those at risk of outbreaks, in conjunction with other prevention and control strategies.
Similar articles
-
Sur D, Lopez AL, Kanungo S, Paisley A, Manna B, Ali M, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Donner A, Ganguly NK, Nair GB, Bhattacharya SK, Clemens JD. Sur D, et al. Lancet. 2009 Nov 14;374(9702):1694-702. doi: 10.1016/S0140-6736(09)61297-6. Epub 2009 Oct 8. Lancet. 2009. PMID: 19819004 Clinical Trial.
-
Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, Sack DA, Svennerholm AM, Holmgren J, Qadri F. Shamsuzzaman S, et al. Vaccine. 2009 Feb 25;27(9):1386-92. doi: 10.1016/j.vaccine.2008.12.041. Epub 2009 Jan 13. Vaccine. 2009. PMID: 19146897
-
Anh DD, Canh DG, Lopez AL, Thiem VD, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Holmgren J, Clemens J. Anh DD, et al. Vaccine. 2007 Jan 22;25(6):1149-55. doi: 10.1016/j.vaccine.2006.09.049. Epub 2006 Sep 29. Vaccine. 2007. PMID: 17055622 Clinical Trial.
-
Vibrio cholerae: lessons for mucosal vaccine design.
Bishop AL, Camilli A. Bishop AL, et al. Expert Rev Vaccines. 2011 Jan;10(1):79-94. doi: 10.1586/erv.10.150. Expert Rev Vaccines. 2011. PMID: 21162623 Free PMC article. Review.
-
[Anticholera vaccines and vaccination].
Ivanoff B, Chaignat CL. Ivanoff B, et al. Bull Soc Pathol Exot. 2002 Dec;95(5):355-8. Bull Soc Pathol Exot. 2002. PMID: 12696375 Review. French.
Cited by
-
Not just an antibiotic target: Exploring the role of type I signal peptidase in bacterial virulence.
Walsh SI, Craney A, Romesberg FE. Walsh SI, et al. Bioorg Med Chem. 2016 Dec 15;24(24):6370-6378. doi: 10.1016/j.bmc.2016.09.048. Epub 2016 Sep 21. Bioorg Med Chem. 2016. PMID: 27769673 Free PMC article.
-
Cordoba Aguilar E, Herrera Rivero M, Rubi A, Arroyo-Helguera O, Coutino Rodriguez R. Cordoba Aguilar E, et al. Jundishapur J Microbiol. 2014 Mar;7(3):e6855. doi: 10.5812/jjm.6855. Epub 2014 Mar 1. Jundishapur J Microbiol. 2014. PMID: 25147681 Free PMC article.
-
Raslan R, El Sayegh S, Chams S, Chams N, Leone A, Hajj Hussein I. Raslan R, et al. Front Public Health. 2017 Oct 25;5:283. doi: 10.3389/fpubh.2017.00283. eCollection 2017. Front Public Health. 2017. PMID: 29119098 Free PMC article. Review.
-
Identification of burden hotspots and risk factors for cholera in India: An observational study.
Ali M, Sen Gupta S, Arora N, Khasnobis P, Venkatesh S, Sur D, Nair GB, Sack DA, Ganguly NK. Ali M, et al. PLoS One. 2017 Aug 24;12(8):e0183100. doi: 10.1371/journal.pone.0183100. eCollection 2017. PLoS One. 2017. PMID: 28837645 Free PMC article.
-
Uptake during an oral cholera vaccine pilot demonstration program, Odisha, India.
Kar SK, Pach A, Sah B, Kerketta AS, Patnaik B, Mogasale V, Kim YH, Rath SB, Shin S, Khuntia HK, Bhattachan A, Puri MK, Wierzba TF, Kaljee LM. Kar SK, et al. Hum Vaccin Immunother. 2014;10(10):2834-42. doi: 10.4161/21645515.2014.971655. Hum Vaccin Immunother. 2014. PMID: 25483631 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical